Novocure

Novocure is a publicly traded medical device company listed on NASDAQ under the ticker NVCR. The company developed a medical technology called Tumor Treating Fields (TTFields) — low-intensity, alternating electric fields designed to disrupt cancer cell division. The company's official headquarters is in Saint Helier, Jersey, with a significant operational presence in New York.

Novocure's primary product is Optune, a wearable medical device intended for home use by patients with glioblastoma (GBM), an aggressive form of brain tumor. The device delivers TTFields through adhesive transducer arrays worn on the scalp continuously. Optune is FDA-approved for recurrent GBM and, in combination with temozolomide chemotherapy, for newly diagnosed GBM. The company sells through direct distribution to oncology centers and hospitals, with reimbursement dependent on health insurance coverage.

Optune is the flagship device approved for GBM. Novocure also received FDA approval for Optune Lua, a TTFields device for malignant pleural mesothelioma in combination with chemotherapy. The company is running multiple clinical trials to evaluate TTFields across additional cancer types, including pancreatic, ovarian, lung, and liver cancers, with the goal of expanding the addressable indications.

Novocure operates in a relatively unique niche — physical oncology treatment that complements chemotherapy and radiation rather than competing directly with drug-based therapies. Its FDA clearances for TTFields provide a meaningful regulatory moat. Expansion into additional cancer indications is the company's primary growth axis.